Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
- Conditions
- Interventions
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2013-04-22
- Lead Sponsor
- Instituto Nacional de Cancer, Brazil
- Target Recruit Count
- 228
- Registration Number
- NCT01836575
- Locations
- 🇺🇸
The Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇧🇷Centro de Pesquisas Oncológicas - CEPON, Florianópolis, Santa Catarina, Brazil
🇧🇷Hospital Lifecenter, Belo Horizonte, Minas Gerais, Brazil
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT01836341
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT01828099
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
- Conditions
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT01828112
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT01809210
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 236
- Registration Number
- NCT01803282
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸University of Southern California (USC), Los Angeles, California, United States
🇺🇸Parkview Research Center, Fort Wayne, Indiana, United States
Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 95
- Registration Number
- NCT01783834
- Locations
- 🇰🇷
Gachon university Gil Medical Center, Incheon, Korea, Republic of
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 39
- Registration Number
- NCT01783197
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 135
- Registration Number
- NCT01774578
- Locations
- 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸Deaconess Clinic, Evansville, Indiana, United States
Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Universität Duisburg-Essen
- Registration Number
- NCT01742767
- Locations
- 🇩🇪
University hospital essen, Essen, Northrhine westphalia, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.